Riskpilot← Back to searchSign inGet full accessHemapal Oy
OYDissolvedY-tunnus 3211568-9Töllinkuja 9Medical specialists activities · NACE 8622Est. 20211 employees
Revenue 2024
EUR 203K
-27% vs 2023
EBITDA margin
26.6%
-47% vs 2023
Equity ratio
95.7%
Financial strength
Net profit 2024
EUR 21K
-71% vs 2023
| Revenue | EUR 203K | -27% |
| EBITDA | EUR 54K | -47% |
| Net profit | EUR 21K | -71% |
| Total assets | EUR 290K | +1% |
| Equity | EUR 278K | +0% |
| Employees | 1 | — |
Legal name
Hemapal Oy
Y-tunnus number
3211568-9
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
14. toukokuuta 2021
Share capital
EUR 0
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Yhtiön toimiala on yleis- ja erikoislääkäripalvelujen tuottaminen potilaille, sairaaloihin, hoitolaitoksiin ja yksityisen terveydenhuollon palvelupisteisiin, alan koulutus-, ja konsultointipalvelujen tuottaminen ja luennointi. Yhtiö voi omistaa, hallita ja vuokrata kiinteistöjä, liike- ja asuinhuoneistoja sekä kulkuneuvoja. Yhtiö voi harjoittaa arvopaperikauppaa.
Address
Töllinkuja 9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 358 | 277 | 203 |
| Staff expenses | −87 | −134 | −102 |
| EBITDA | 231 | 101 | 54 |
| Depreciation & amort. | −19 | −11 | −8 |
| EBIT | 211 | 90 | 46 |
| Net financials | −1 | 1 | −11 |
| Profit before tax | 210 | 91 | 34 |
| Tax | 42 | 18 | 13 |
| Net profit | 167 | 73 | 21 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 244 | 288 | 290 |
| Equity | 224 | 279 | 278 |
| Long-term debt | — | 0 | 0 |
| Short-term debt | 20 | 9 | 12 |
| Total debt | 20 | 9 | 12 |
EBITDA margin
26.6%
This company
15.8%
Market median
+68% vs market
20222024
Equity ratio
95.7%
This company
38.2%
Market median
+151% vs market
20222024
Return on equity
7.6%
This company
18.4%
Market median
-59% vs market
20222024
Net profit margin
10.4%
This company
8.1%
Market median
+28% vs market
20222024
Asset turnover
0.70×
This company
1.12×
Market median
-38% vs market
20222024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
TI Deputy Member | Deputy Member | 2021 |
ME Chief Executive Officer | Chief Executive Officer | 2021 |
JA Deputy auditor | Deputy auditor | 2025 |
KK Audit | Audit | 2025 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Hemapal Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tapani Ilpo Antero Härö | Deputy Member | 0 companies |
| Maria Elisabet Rämet | Chief Executive Officer | 0 companies |
| Jose Adam Juhani Kautonen | Deputy auditor | 0 companies |
| Kiri Kasperi Sopanen | Audit | 0 companies |